论文部分内容阅读
目的:探讨阿仑膦酸钠联合碳酸钙D3片对糖尿病性骨质疏松症(DOP)患者骨密度(BMD)、骨代谢指标的影响。方法:将110例DOP患者随机分为观察组和对照组,每组55例。对照组患者使用降糖药并给予碳酸钙D3片,观察组在对照组的基础上加用阿仑膦酸钠,两组患者均治疗6个月。比较两组患者治疗效果及治疗前、后BMD、骨代谢指标水平变化情况。结果:治疗后,观察组总有效率为96.36%,显著高于对照组总有效率的83.64%(P<0.05)。治疗前,两组患者股骨颈、股骨粗隆间BMD的比较差异无统计学意义(P>0.05);治疗后,两组患者股骨颈、股骨粗隆间BMD与治疗前相比均明显增加(均P<0.05),且观察组股骨颈、股骨粗隆间BMD明显高于对照组(P<0.05)。治疗前,两组患者骨代谢指标骨源性碱性磷酸酶(BAP)和骨钙素(BGP)水平比较差异无统计学意义(P>0.05);治疗后,两组BAP、BGP水平均显著升高(P<0.05),且与对照组相比,观察组BAP、BGP水平上升更显著(P<0.05)。结论:阿仑膦酸钠联合碳酸钙D3片对DOP患者治疗效果较好,且可明显改善患者BMD及骨代谢指标水平。
Objective: To investigate the effect of alendronate and calcium D3 on bone mineral density (BMD) and bone metabolism in patients with diabetic osteoporosis (DOP). Methods: 110 DOP patients were randomly divided into observation group and control group, 55 cases in each group. Patients in the control group were given hypoglycemic agents and given D3 tablets of calcium carbonate. The observation group was given alendronate on the basis of the control group, and both groups were treated for 6 months. The treatment effect and the changes of BMD and bone metabolic index before and after treatment were compared between the two groups. Results: After treatment, the total effective rate in the observation group was 96.36%, which was significantly higher than that in the control group (83.64%, P <0.05). Before treatment, BMD of femoral neck and femoral intertrochanter was no significant difference between the two groups (P> 0.05); after treatment, the BMD of femoral neck and femur in both groups were significantly increased compared with before treatment P <0.05). The BMD of the femoral neck and femur in the observation group was significantly higher than that of the control group (P <0.05). Before treatment, there was no significant difference in bone metabolism index (BAP) and osteocalcin (BGP) between the two groups (P> 0.05). After treatment, the levels of BAP and BGP in both groups were significant (P <0.05). Compared with the control group, the BAP and BGP levels in the observation group increased more significantly (P <0.05). Conclusion: Alendronate combined with D3 of calcium carbonate has good therapeutic effect on DOP patients, and can significantly improve the level of BMD and bone metabolism index in patients.